 SAN DIEGO, May 18, 2021 PRNewswire -- Viracta Therapeutics, Inc. Nasdaq: VIRX Viracta, a precision oncology company targeting virus-associated malignancies, will host a key opinion leader KOL webinar on nanatinostat and valganciclovir for the treatment of relapsedrefractory Epstein-Barr virus EBV-positive lymphoma on Thursday, May 20, 2021 at 2:00 PM ET. The call will feature a presentation by KOLs Pierluigi Porcu, M.D. 